Hormonal
Inhibiting PCSK9, NF-κB, and NLRP3 reduces cholesterol and inflammation, providing cardioprotection.
For cardiovascular protection, medications that lower cholesterol (like PCSK9 inhibitors) and reduce inflammation (targeting NF-κB or NLRP3) are effective strategies. These treatments help manage risk factors associated with heart disease and metabolic disorders. Discuss with your healthcare provider if these targeted therapies are suitable for your cardiovascular health.
Concurrently, inhibiting PCSK9, NF-κB, and NLRP3 helps to lower cholesterol and reduce harmful inflammation, offering cardioprotection.
Why this rating
The paper cites clinical outcome trials confirming PCSK9 inhibition lowers LDL and ASCVD risk.
Source
Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection
Errikos Petsas et al. · Molecules · 2025
DOI 10.3390/molecules30214240
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →